Trial reportJournal of immunology (Baltimore, Md. : 1950)2020
An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report.
Trial report in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Probable cerebral amyloid angiopathy - related inflammation in a 32-year-old woman with down syndrome.Neurogenetics · 2026Article
- Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.Heliyon · 2025Review
- Protocol of a randomized, single-blind, controlled trial of an 18-month, home-based, high-intensity, exercise intervention in older, cognitively unimpairedFrontiers in aging neuroscience · 2025Article
- Assessing the Relationship of Brain Metabolites to Cortical Thickness and Dementia Symptoms in Adults with Down Syndrome: A Pilot Study.Brain sciences · 2024Article
- Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.EBioMedicine · 2024Review
- Emerging Microglial Therapies and Targets in Clinical Trial.Advances in neurobiology · 2024Review
- Soluble Trem2 is a negative regulator of erythrophagocytosis after intracerebral hemorrhage in a CD36 receptor recycling manner.Journal of advanced research · 2023Article
- Review
- Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Serum sTREM2: A Potential Biomarker for Mild Cognitive Impairment in Patients With Obstructive Sleep Apnea.Frontiers in aging neuroscience · 2022Article
- Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease.Frontiers in cellular neuroscience · 2022Review
- Rodent Modeling of Alzheimer's Disease in Down Syndrome:Frontiers in neuroscience · 2022Review
- The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.Scientific reports · 2021Article
- TREM2 alters the phagocytic, apoptotic and inflammatory response to AβMolecular immunology · 2021Article
- Nerve Growth Factor Compromise in Down Syndrome.Frontiers in aging neuroscience · 2021Review
- Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.Brain : a journal of neurology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Individuals with Down syndrome (DS) develop Alzheimer's disease (AD)-related neuropathology, characterized by amyloid plaques with amyloid β (Aβ) and neurofibrillary tangles with tau accumulation. Peripheral inflammation and the innate immune response are elevated in DS. Triggering receptor expressed in myeloid cells 2 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.